What was the lawsuit about and why has it been dismissed?

The lawsuit was initiated by Gilead Sciences against Lupin Ltd. for patent infringement related to generic versions of Gilead's HIV medications Truvada® and Viread®. The lawsuit has been dismissed because Lupin amended its applications to the FDA, agreeing not to market generic versions until after the expiration of Gilead's relevant patents in January 2018. This agreement led to a joint request for dismissal by both parties.

What is the impact of this dismissal on Gilead's Truvada and Viread sales?

The dismissal is a positive development for Gilead as it safeguards the company's market exclusivity for Truvada and Viread until at least January 2018. This means that generic competition for these key HIV treatments will be prevented until that date, protecting Gilead's significant revenue generated from these products.

What does 'pediatric exclusivity' mean in this context?

Pediatric exclusivity is an extension of patent protection granted by the FDA for drugs for which studies in children have been conducted. In this case, it means that the expiration date of January 2018 also accounts for this additional period of market exclusivity related to pediatric studies.

GILD 8-K SEC Disclosure

Q: Does this dismissal affect all of Gilead's patents related to Truvada and Viread?

No, the dismissal specifically pertains to the patents covering tenofovir disoproxil fumarate. Gilead's separate patent infringement lawsuit against Lupin for patents associated with emtricitabine, another component of Truvada, is still active and ongoing.

Summary

Gilead Sciences, Inc. (GILD) announced the dismissal of a patent infringement lawsuit against Lupin Ltd. concerning generic versions of Truvada® and Viread®. In 2012, Lupin submitted applications for generic versions, challenging the validity of Gilead's patents. Gilead subsequently filed lawsuits for patent infringement. However, in May 2014, Lupin amended its applications to defer marketing generic Truvada and Viread until after the expiration of four key patents related to tenofovir disoproxil fumarate in January 2018, which includes pediatric exclusivity. This change led to a joint motion for dismissal granted by the U.S. District Court for the Southern District of New York on May 30, 2014. This development is positive for Gilead as it ensures continued market exclusivity for Truvada and Viread until at least January 2018, thereby protecting its revenue streams from these important HIV medications. While the lawsuit concerning tenofovir disoproxil fumarate patents has been dismissed, it's important to note that Gilead's separate patent infringement lawsuit against Lupin for emtricitabine patents remains active. Investors should monitor this ongoing litigation, although the primary concern regarding the tenofovir disoproxil fumarate patents has been resolved favorably.

Key Highlights

1Gilead Sciences has successfully resolved a patent infringement lawsuit filed against Lupin Ltd. regarding generic versions of Truvada® and Viread®.
2Lupin Ltd. amended its abbreviated new drug applications (ANDAs) to delay the marketing of generic Truvada and Viread.
3The delay in marketing generic versions extends until after the expiration of key patents for tenofovir disoproxil fumarate in January 2018, including pediatric exclusivity.
4The U.S. District Court for the Southern District of New York granted a Joint Motion for Order of Dismissal on May 30, 2014.
5This dismissal protects Gilead's market exclusivity for Truvada and Viread until at least January 2018.
6A separate patent infringement lawsuit filed by Gilead against Lupin concerning emtricitabine patents remains ongoing.

GILEAD SCIENCES, INC. 8-K Report, Corporate Update (Jun 2, 2014)

Summary

Key Highlights

Frequently Asked Questions